Amro chemical fiber provides a solution for reversing liver fibrosis

In the TCM group, led by Professor Chi Xiaoling of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, the TCM dialectical treatment of blocking hepatitis B-related liver fibrosis study was a double-blind, randomized, placebo-controlled trial with the participation of 18 units across the country. A total of 270 patients with mild liver fibrosis (G<2, S≤2) with chronic hepatitis B were included, including 180 patients in the amro chemical fiber treatment group and 90 in the control group. After 48 weeks of treatment, 147 patients (106 patients in the treatment group and 41 patients in the control group) completed secondary liver puncture. The results showed that compared with the control group, the FibroScan value of the amlo chemical fiber group was significantly lower (5.63±2.33 vs. 6.54±3.80, P=0.036), and the pathological stage reversal rate of liver fibrosis was higher after 48 weeks of treatment (37.7% vs. 19.5%, P=0.037). The treatment of liver depression and spleen deficiency, blood stasis type CHB mild liver fibrosis (G<2, S≤2) patients have a good effect.

In general, the two major science and technology research projects of Chinese and Western medicine in the Twelfth Five-Year Plan have the characteristics of combined (Chinese and Western medicine)/non-combined (Chinese and Western medicine alone) and blind/open (blind reading). A total of 760 patients were included in traditional Chinese and Western medicine, comprehensively covering mild, moderate and severe liver fibrosis and cirrhosis, and have obvious advantages in disease course coverage and sample size. Evidence-based evidence is more convincing.

We have consolidated our achievements in the major projects for the 13th Five-Year Plan

On the basis of the achievements of the "Twelfth Five-Year Plan" major science and technology projects, in 2018, the national "Thirteenth Five-Year Plan" major science and technology projects of Anluo Chemical Fiber "Clinical Efficacy evaluation of the primary prevention and treatment program of TCM Syndrome Differentiation to block and reverse chronic Hepatitis B liver fibrosis" (Chinese Medicine group) and "Accurate Diagnosis and reversal of Hepatitis B liver fibrosis/cirrhosis Research" (Western Medicine group) were officially launched. The Western Medicine group, led by Peking University First Hospital, aims to conduct an expanded sample size study in patients with F≥3 and develop a treatment regimen to reverse significant liver fibrosis/cirrhosis.

A total of 585 CHB patients eligible for enrollment were included in the study from 33 clinical units, including 393 cases in the ETV+ALHX group and 192 cases in the ETV monotherapy group. After 98 weeks of treatment, 202 cases in the ETV+ALHX group and 94 cases in the ETV group were finally included in the analysis. The results showed that the improvement rate of inflammation before and after treatment in the ETV+ALHX group was significantly improved compared with that in the ETV group (66.83% vs 52.13%, P=0.0158) and the reversal rate of liver fibrosis in baseline F3-4 patients before and after treatment (49.01% vs 17.19%, P=0.020). In addition, there were 1 F0 patient and 17 F1 patients in the ETV+ALHX group, while only 3 F1 patients in the ETV group, suggesting a stronger reversal of liver fibrosis in the combined group. Therefore, for CHB patients with significant liver fibrosis, it is recommended to start antiviral therapy along with anti-fibrosis therapy to delay or reverse the liver fibrosis process.

A number of studies continue to write the legend, Amro chemical fiber improved patient survival for 5 years

A meta-analysis involving 26 articles and 2663 patients with hepatitis B cirrhosis at Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, showed that Amro combined with Entecavir (1339 cases in ETV+ALHX group) reduced portal vein diameter, spleen thickness, and improved the improvement rate of portal vein diameter and splenic vein diameter. Both were significantly better than Entecavir monotherapy (1324 cases in ETV group), with statistical significance (P<0.05), and high safety. It is suggested that the combination of entecavir and amro is of great significance in the treatment of liver fibrosis and delaying the progression of liver cirrhosis.

On the basis of delaying the disease progression of patients, the combination of amro and Entecavir further improved the survival rate of patients. A 5-year efficacy analysis of Entecavir combined with Entecavir in treatment of 56 patients with decompensated hepatitis B cirrhosis in Yuxi People's Hospital of Yunnan Province showed that the 5-year survival rate of Entecavir combined with Entecavir was 67.85% (38/56). Compared with 26.19% (11/42) in Entecavir monotherapy group, it was significantly increased by 41.66% (P < 0.01), which improved the survival rate of patients, and had important clinical significance for the recovery and stability of patients with decompensated hepatitis B cirrhosis.

Follow evidence-based guidelines and norms